Amarin Corporation PLC
423 articles with Amarin Corporation PLC
-
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
5/16/2022
Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022.
-
Amarin to Present at Two Upcoming Investor Conferences - May 12, 2022
5/12/2022
Amarin Corporation plc announced that Karim Mikhail, Amarin’s president and chief executive officer, will present at two upcoming investor conferences.
-
Amarin Reports First Quarter 2022 Financial Results and Provides Business Update
5/4/2022
Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2022 and provided an update on company operations.
-
New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)
5/3/2022
Amarin Corporation plc announced the publication in the Journal of the American College of Cardiology of a new REDUCE-IT® data analysis further strengthening evidence of the benefits of icosapent ethyl in adult patients most at risk of suffering from a potentially fatal or non-fatal cardiovascular event.
-
Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)
4/26/2022
Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for the terms and conditions under which VASCEPA® (icosapent ethyl) would qualify for public market reimbursement in Canada.
-
Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022
4/19/2022
Amarin Corporation plc today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's first quarter 2022 financial results on Wednesday, May 4, 2022 at 8:00 a.m. ET.
-
Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes
4/1/2022
Amarin Corporation plc announced in vitro research results suggesting that Eicosapentaenoic Acid, in combination with widely prescribed statins, contributed to a reduction in lipid oxidation in membranes in a manner that may be enhanced with the use of these statins.
-
Amarin Receives Reimbursement for VAZKEPA® in Sweden
3/28/2022
Amarin Corporation plc announces that the Company received its first national reimbursement in a European country for VAZKEPA® in Sweden and provides an update on the status of its international expansion strategy, including several regulatory filing and reimbursement updates for VASCEPA®/VAZKEPA globally.
-
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology’s 71st Annual Scientific SessionAmarin-Supported Research and Analyses to Be Featured in Six Presentations
3/21/2022
Amarin Corporation plc (NASDAQ:AMRN) today announced a diverse and full slate of supported and/or funded research on VASCEPA®/VAZKEPA (icosapent ethyl) to be presented in six posters at the American College of Cardiology’s 71st Annual Scientific Session in Washington, DC, April 2-4, 2022.
-
Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention
3/10/2022
Amarin Corporation plc (NASDAQ:AMRN) today announced the publication of new REDUCE-IT data analysis that helps support the clinical benefits of icosapent ethyl (IPE) for patients who have received a percutaneous coronary intervention (PCI) and are at high risk for experiencing a stroke, heart attack, or fatal cardiovascular (CV) event.
-
Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
3/1/2022
Amarin Corporation plc, announced financial results for the quarter and year ended December 31, 2021 and provided an update on company operations.
-
Amarin to Participate in Cowen 42nd Annual Health Care Conference
2/25/2022
Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to participate virtually in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7 from 9:10 AM – 9:40 AM ET.
-
JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level
2/24/2022
JAMA Network Open has published “Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment,”1 which evaluated the more than 8,000 patients recruited to participate in the REDUCE-IT® clinical trial.
-
Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022
2/15/2022
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022 at 8:00 a.m. ET.
-
Amarin Provides Preliminary 2021 Revenue and Outlook for 2022
1/10/2022
Amarin Corporation plc provided a business update, including preliminary unaudited full-year 2021 revenue results.
-
Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Amarin Corporation plc is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 am ET.
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021
11/16/2021
Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at the American Heart Association (AHA) Scientific Sessions 2021, which took place virtually from November 13-15, 2021.
-
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease Presented in Rapid Fire Oral Session Presentation at the AHA Scientific Sessions 2021
11/15/2021
Amarin Corporation plc announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA in patients with prior peripheral artery disease at risk for major adverse cardiovascular events were delivered in a Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021, which took place virtually from November 13-15, 2021.
-
Amarin to Present at Two Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Amarin Corporation plc announced that Karim Mikhail, president and chief executive officer of Amarin, and Michael Kalb, chief financial officer of Amarin, are scheduled to participate in the following upcoming investor conferences.